Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEARCA:ALAI NASDAQ:EDOC NYSEARCA:LRNZ NASDAQ:OZEM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALAIAlger AI Enablers & Adopters ETF$32.00-3.5%$30.10$18.73▼$33.60$86.82M1.9926,891 shs102,809 shsEDOCGlobal X Telemedicine & Digital Health ETF$10.42-0.8%$10.59$8.50▼$11.91$34.11M0.8824,744 shs18,299 shsLRNZTrueShares Technology, AI & Deep Learning ETF$43.66-1.7%$43.47$28.58▼$45.99$34.06M1.136,515 shs4,057 shsOZEMRoundhill GLP-1 & Weight Loss ETF$24.25+0.5%$25.72$20.01▼$29.21$32.01MN/A13,094 shs35,582 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALAIAlger AI Enablers & Adopters ETF-3.53%-0.12%+5.79%+28.46%+50.66%EDOCGlobal X Telemedicine & Digital Health ETF-0.83%-3.29%-2.86%+3.30%+13.79%LRNZTrueShares Technology, AI & Deep Learning ETF-1.71%-3.96%-0.41%+15.50%+18.42%OZEMRoundhill GLP-1 & Weight Loss ETF+0.54%-9.82%-5.24%-5.09%-10.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALAIAlger AI Enablers & Adopters ETFN/AN/AN/AN/AN/AN/AN/AN/AEDOCGlobal X Telemedicine & Digital Health ETFN/AN/AN/AN/AN/AN/AN/AN/ALRNZTrueShares Technology, AI & Deep Learning ETFN/AN/AN/AN/AN/AN/AN/AN/AOZEMRoundhill GLP-1 & Weight Loss ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALAIAlger AI Enablers & Adopters ETF 2.91Moderate Buy$32.00N/AEDOCGlobal X Telemedicine & Digital Health ETF 2.64Moderate Buy$10.42N/ALRNZTrueShares Technology, AI & Deep Learning ETF 2.74Moderate Buy$43.66N/AOZEMRoundhill GLP-1 & Weight Loss ETF 2.62Moderate Buy$24.25N/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALAIAlger AI Enablers & Adopters ETFN/AN/AN/AN/AN/AN/AEDOCGlobal X Telemedicine & Digital Health ETFN/AN/AN/AN/AN/AN/ALRNZTrueShares Technology, AI & Deep Learning ETFN/AN/AN/AN/AN/AN/AOZEMRoundhill GLP-1 & Weight Loss ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALAIAlger AI Enablers & Adopters ETFN/AN/A29.71∞N/AN/AN/AN/AN/AEDOCGlobal X Telemedicine & Digital Health ETFN/AN/A42.80∞N/AN/AN/AN/AN/ALRNZTrueShares Technology, AI & Deep Learning ETFN/AN/A54.00∞N/AN/AN/AN/AN/AOZEMRoundhill GLP-1 & Weight Loss ETFN/AN/A22.34∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALAIAlger AI Enablers & Adopters ETF$0.170.53%N/AN/AN/AEDOCGlobal X Telemedicine & Digital Health ETFN/AN/AN/AN/AN/ALRNZTrueShares Technology, AI & Deep Learning ETF$0.060.14%N/AN/AN/AOZEMRoundhill GLP-1 & Weight Loss ETF$0.050.21%N/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALAIAlger AI Enablers & Adopters ETFN/AEDOCGlobal X Telemedicine & Digital Health ETFN/ALRNZTrueShares Technology, AI & Deep Learning ETFN/AOZEMRoundhill GLP-1 & Weight Loss ETFN/AInsider OwnershipCompanyInsider OwnershipALAIAlger AI Enablers & Adopters ETFN/AEDOCGlobal X Telemedicine & Digital Health ETFN/ALRNZTrueShares Technology, AI & Deep Learning ETFN/AOZEMRoundhill GLP-1 & Weight Loss ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALAIAlger AI Enablers & Adopters ETFN/A2.71 millionN/AN/AEDOCGlobal X Telemedicine & Digital Health ETF147,0003.61 millionN/AOptionableLRNZTrueShares Technology, AI & Deep Learning ETFN/A780,000N/ANot OptionableOZEMRoundhill GLP-1 & Weight Loss ETFN/A1.32 millionN/AN/AALAI, OZEM, EDOC, and LRNZ HeadlinesRecent News About These CompaniesHow to avoid nausea on Ozempic and GLP-1 medicationsMarch 17, 2025 | msn.comScientists Discover Potential Ozempic Rival That Could Help People Lose Weight With Less NauseaMarch 16, 2025 | gizmodo.comGEmployers face pressure to add coverage of Ozempic, other weight-loss drugsMarch 12, 2025 | bizjournals.comHere’s why Ozempic maker’s new weight-loss drug isn’t good enough for investorsMarch 10, 2025 | msn.comNaturally occurring molecule rivals Ozempic in weight loss, sidesteps side effectsMarch 7, 2025 | msn.comMore yogurt and nuts, less alcohol and snack foods: How GLP-1 medications like Ozempic are influencing people’s food spending habitsMarch 5, 2025 | yahoo.com5 Sector ETFs Up 10% Despite February's Market SlumpMarch 3, 2025 | zacks.comDrug compounders sue over weight loss drugs’ removal from FDA shortage listFebruary 25, 2025 | msn.comHow experiments with gila monster venom led to blockbuster weight loss drugs like OzempicFebruary 24, 2025 | whyy.orgWWeight-loss drugs aren’t just slimming waists. They’re shifting the economy.February 23, 2025 | washingtonpost.comFDA gives compounders short reprieve as Novo Nordisk GLP-1 supply normalizesFebruary 21, 2025 | seekingalpha.comYearslong shortage of popular weight-loss and diabetes drugs is resolved, FDA saysFebruary 21, 2025 | msn.comNovel antibody could help prevent bone, muscle loss due to GLP-1 drugsFebruary 18, 2025 | medicalnewstoday.comMIs Ozempic safe for weight loss? What doctors want you to know about blockbuster drugFebruary 15, 2025 | aol.comAWeight-Loss Drugs Like Ozempic Can Help Alcohol AddictionFebruary 13, 2025 | msn.comThe 2 sides of Ozempic — weight loss success stories and health nightmares in KentuckyFebruary 11, 2025 | wdrb.comW(OZEM) Investment AnalysisFebruary 1, 2025 | news.stocktradersdaily.comNAbout half of Americans approve of using weight-loss drugs to treat obesity, AP-NORC poll findsJanuary 31, 2025 | msn.comOzempic vs. Semaglutide: 10 Weight Loss Medications Compared for 2025January 30, 2025 | omaha.comOWhy Weight-Loss Drugs Could Be Game-Changers for Your Investment PortfolioJanuary 30, 2025 | msn.comMedia Sentiment Over TimeALAI, OZEM, EDOC, and LRNZ Company DescriptionsAlger AI Enablers & Adopters ETF NYSEARCA:ALAI$32.00 -1.17 (-3.53%) Closing price 08/1/2025 04:10 PM EasternExtended Trading$32.39 +0.39 (+1.22%) As of 08/1/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Alger AI Enablers & Adopters ETF (ALAI) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is actively managed, investing in firms benefiting from developing, integrating or enabling artificial intelligence (AI) technology. The fund seeks long-term capital growth through fundamental research ALAI was launched on Apr 4, 2024 and is issued by Alger.Global X Telemedicine & Digital Health ETF NASDAQ:EDOC$10.42 -0.09 (-0.83%) As of 07/31/2025The Global X Telemedicine & Digital Health ETF (EDOC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap weighted index of companies in the global health care industry with high exposure to telemedicine & digital health. EDOC was launched on Jul 29, 2020 and is managed by Global X.TrueShares Technology, AI & Deep Learning ETF NYSEARCA:LRNZ$43.66 -0.76 (-1.71%) Closing price 08/1/2025 04:10 PM EasternExtended Trading$43.28 -0.38 (-0.87%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The TrueShares Technology, AI and Deep Learning ETF (LRNZ) is an exchange-traded fund that is based on the Nasdaq Composite TR index. The fund is actively managed and invests in global equities focused on artificial intelligence and deep learning. LRNZ was launched on Feb 28, 2020 and is managed by TrueShares.Roundhill GLP-1 & Weight Loss ETF NASDAQ:OZEM$24.25 +0.13 (+0.54%) As of 08/1/2025 03:59 PM EasternThe Roundhill GLP-1 & Weight Loss ETF (OZEM) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies from around the world involved in pharmaceutical drugs and supplements used for weight management. OZEM was launched on May 21, 2024 and is issued by Roundhill. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
